

AusCann Investor Webinar Recording

27 September 2019 – Leading medical cannabis company **AusCann Group Holdings Limited** (ASX:AC8) (AusCann or ‘the Company’) is pleased to advise that a recording of the webinar hosted on Wednesday 25 September 2019 is now available under the title ‘Investor Webinar’ at the bottom of the page on the following link:

<https://auscann.com.au/investors/interviews-and-presentations/>

The Investor Webinar was conducted by AusCann’s CEO, Mr Ido Kanyon, who provided an overview of the Company’s strategy and addressed questions from shareholders.

ENDS

For more information, please contact:

For Investment Enquiries

Quentin Megson
Chief Operating and Financial Officer
info@auscann.com.au
+61 8 9561 8834

For Media Enquiries

Elodie Castagna
FTI Consulting
elodie.castagna@fticonsulting.com
+61 8 9321 8533

ABOUT AUSCANN

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based Pharmaceutical Company focused on the development, production, and marketing of cannabinoids-based pharmaceuticals within Australia and internationally. AusCann:

- **transforms** the way Medical Cannabis is dispensed today by making Cannabinoids-based Pharmaceutical dose forms accessible to patients, physicians and healthcare providers worldwide.
- **enables** physicians to treat their patients with a reliable, stable, well-characterized pharmaceutical product, monitor treatment results and adjust treatment algorithm using a portfolio of products and formulations.
- **holds** all required Medical Cannabis licenses to operate in Australia following its incorporation in 2014.
- **is targeting** the treatment of chronic pain in Australia initially, whilst exploring global export opportunities and expansion into additional medical areas.